HRT FINANCIAL LP
Institutional investor · Portfolio as of Q2 2025
Top Holdings2,511 positions
STATE STR SPDR S&P 500 ETF T | 8.8M | $5.5B | 24.0% | $520.67 | +17.07% | 26 qtrssince 2019-Q1 | Increased 90 |
INVESCO QQQ TRUST SERIES 1 | 3.1M | $1.7B | 7.6% | $477.17 | +14.58% | 20 qtrssince 2020-Q3 | Increased 100 |
APPLOVIN CORP | 1.6M | $552.1M | 2.4% | $334.62 | -20.47% | 3 qtrssince 2024-Q4 | Increased 85 |
PALANTIR TECHNOLOGIES INC | 2.5M | $340.8M | 1.5% | $98.22 | +33.11% | 2 qtrssince 2025-Q1 | Increased 64 |
ISHARES TR | 1.5M | $315.9M | 1.4% | $197.25 | +7.99% | 19 qtrssince 2020-Q4 | Decreased 0 |
| 592,100 | $294.5M | 1.3% | — | — | — | Increased 77 | |
THOMSON REUTERS CORP. | 1.4M | $279.3M | 1.2% | $179.46 | +7.17% | 3 qtrssince 2024-Q4 | Increased 78 |
| 1.7M | $271.6M | 1.2% | — | — | — | Increased 61 | |
| 293,400 | $216.6M | 1.0% | — | — | — | Increased 68 | |
| 989,700 | $203.1M | 0.9% | — | — | — | Increased 64 | |
| 1.1M | $197.8M | 0.9% | — | — | — | Increased 69 | |
| 886,000 | $194.4M | 0.9% | — | — | — | Increased 68 | |
ROBINHOOD MKTS INC | 2M | $191.2M | 0.8% | $73.97 | +12.26% | 3 qtrssince 2024-Q4 | Increased 69 |
| 951,100 | $167.6M | 0.7% | — | — | — | Increased 69 | |
| 1.1M | $166.5M | 0.7% | — | — | — | Increased 44 | |
AZEK CO INC | 2.8M | $154.1M | 0.7% | — | — | 1 qtr | New 59 |
ALPHABET INC | 722,489 | $128.2M | 0.6% | $176.13 | +0.37% | 8 qtrssince 2023-Q3 | Increased 60 |
CME GROUP INC | 461,154 | $127.1M | 0.6% | $265.30 | 0.00% | 1 qtr | New 59 |
| 562,600 | $115.4M | 0.5% | — | — | — | Decreased 0 | |
| 416,700 | $114.9M | 0.5% | — | — | — | Increased 68 |
HRT FINANCIAL LP manages $22.7B across 2511 positions as of Q2 2025. Top holdings: SPY (24.0%), QQQ (7.6%), APP (2.4%). Fund DNA: Diversified Scout. HoldingsIntel Score: 2/5.0.
Active quarter - 1360 new positions, 1306 exits, 641 increased. Top move: QQQ (INCREASED, conviction 100). Portfolio: $22.7B across 2511 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR